Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5683186 | 0.88 | ADORA2A (0.45) | HSPA1APABPC1NR1H2NR1H3ALDH1A1 | |
| SCHEMBL14777408 | 0.86 | NR1H2 (0.53) | HSPA1APABPC1NR1H2NR1H3RAD51 | |
| SCHEMBL30286549 | 0.77 | NR1H2 (0.50) | HSPA1APABPC1NR1H2NR1H3RAD51 | |
| SCHEMBL30595508 | 0.77 | MGLL (0.50) | NR1H2NR1H3RAD51ALDH1A1NPSR1 | |
| SCHEMBL15437908 | 0.77 | RAD51 (0.71) | NR1H2NR1H3RAD51ALDH1A1NPSR1 | |
| SCHEMBL15437877 | 0.77 | ESR1 (0.47) | HSPA1APABPC1NR1H2NR1H3RAD51 | |
| SCHEMBL27575223 | 0.76 | NR1H2 (0.45) | HSPA1APABPC1NR1H2NR1H3RAD51 | |
| SCHEMBL5068959 | 0.74 | MGLL (0.46) | HSPA1APABPC1NR1H2NR1H3RAD51 | |
| SCHEMBL16280099 | 0.73 | MGLL (0.62) | HSPA1APABPC1ALDH1A1NPSR1KMT2A | |
| SCHEMBL15437728 | 0.73 | RAD51 (0.49) | NR1H2NR1H3RAD51ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104093779-A | Synthetic resin, and varnish, prepreg and laminate produced therefrom | ISOLA USA CORP | 2014-10-08 | — | — | CN | claimed |
| CN-104093779-A | Synthetic resin, and varnish, prepreg and laminate produced therefrom | ISOLA USA CORP | 2014-10-08 | — | — | CN | disclosed |
| US-20060252045-A1 | Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby | WYETH | 2006-11-09 | — | — | US | disclosed |
| WO-2005028678-A9 | METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY | WYETH CORP (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1636388-A2 | METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY | Wyeth (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005028678-A2 | METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY | WYETH (US) | 2005-03-31 | — | — | WO | disclosed |
| US-6719520-B2 | FOR INHIBITION OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3); TREATMENT AND PROPHYLAXIS FOR DIABETES, CHRONIC NEURODEGENERATIVE CONDITIONS, MOOD DISORDERS SUCH AS SCHIZOPHRENIA AND MANIC DEPRESSION AND HAIR LOSS AND CANCER | SMITHKLINE BEECHAM CORPORATION | 2004-04-13 | — | — | US | disclosed |
| US-20040010031-A1 | Novel method and compounds | SMITHKLINE BEECHAM P.L.C. | 2004-01-15 | — | — | US | disclosed |
| EP-1119548-A1 | PYRROLE-2,5-DIONES AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021927-A2 | PYRROLE-2,5-DIONES AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010031-A1 | Novel method and compounds | GSK3A, GSK3B, GSKIP | HSPA1A 3140/4885PABPC1 4863/4885NR1H2 74/4885 |
| US-20060252045-A1 | Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby | BMP4, BMP2, BMP6 | HSPA1A 1361/4885PABPC1 4425/4885NR1H2 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.